Please tell us about your clinical experience. How many patients with hATTR Amyloidosis do you see on a yearly basis? What is the standard of care, and can you tell us more about disease severity and burden, prevalence? What new developments are you excited about in this space?

What % of patients achieve good outcomes with standard of care medication?

What treatment shows best results on the Neuropathy Impairment, Quality of Life (QoL), Gait Speed, Nutritional Status and Overall Disability scores?

5% of the patients with primary amyloidosis survive beyond 10 years. Have you had such success stories in your patients, and what would you attribute that to? What percent of patients can go into remission with drug therapy?

Can you talk to us more about the potential of RNAi therapeutics like Vutrisiran, where do you see them standing in the near future? What is the likelihood of reducing deposition and cleaning of TTR amyloid deposits in tissues?

Alnylam boasts about increased potency and high metabolic stability, that would allow for infrequent subcutaneous injections. How much would that weigh in the balance when deciding on a treatment course for your patients?

Could you please discuss the HELIOS-A 18-Month Study Results, posted on Jan 21, treported cardiac improvement when taking vutrisiran?